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CAN HEALTHY TRANSPLANTED TISSUE BE USED TO RESTORE MOTOR
FUNCTION IN PATIENTS WITH PARKINSON’S DISEASE?
Aliza Erlbaum
Abstract:
Parkinson’s Disease is a condition that disrupts the lives the many people. The disease is
characterized by a loss of dopamine producing neurons in the pars compacta of the substantia nigra of
the ventral midbrain, and symptoms include a lack of motor control and rigidity in motion. Currently,
there are many treatments available to treat patients with Parkinson’s disease. However, each treatment
involves many adverse side effects that most wish to avoid. Science is discovering possible innovative,
alternative options to treat Parkinson’s disease such as the transplantation of healthy dopaminergic
neurons directly into the striatum of the patient. Methods include using stem cells from original fetal
sources, embryonic stem cells, induced pluripotent cells, or directly converting somatic cells into
dopaminergic neurons. This study explores each possible treatment method along with the risks and
advantages associated with each one, citing original experimental data and significant review articles.
The results of this study do suggest potential in this new area of treatment for Parkinson’s disease, yet
much perfection of techniques and additional research must be completed before this idea can be used as
a standardized treatment plan.

Introduction:
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine
producing neurons, primarily in the pars compacta of the substantia nigra in the ventral midbrain (Aguila
et.al 2012). The substantia nigra is a part of a cohesive group of nuclei in the brain commonly referred
to as the basal ganglia. Other nuclei of the basal ganglia include the caudate, putamen, globus pallidus,
and the nucleus accumbens (Knierim 2012). In addition to the death of neurons in the substantia nigra,
resulting in a loss of dopamine and melanin, this damage caused by PD can spread to other parts of the
brain as well and affect other neurotransmitters and instigate other symptoms. Parkinson’s disease can
also be characterized by a collection of protein consisting bodies found in the brainstem of the patient
commonly referred to as Lewy bodies. Although the presence of Lewy bodies is now considered an
acceptable neurological disorder of PD, there is still no identifiable direct relationship between their
existence and the physical symptoms of Parkinson’s disease (Aguila et. al 2012). The nigostriatal
pathway, the pathway which transports dopamine from the substantia nigra to the striatum, is largely
associated with motor control. Therefore, some primary features of PD are rigidness, trouble with simple
motor movement such as standing, and tremor. Over the years various treatments have been used to treat
Parkinson’s disease. Most of these treatments and medications involve either replacement of dopamine
in the substantia nigra, or a chemical that can imitate the action of dopamine in the ventral midbrain.
However, although most of these methods do temporarily relieve some symptoms of PD, the side effects
of the medication, and the inability of the therapy to last permanently and alleviate all symptoms begs
scientists to pursue other alternative treatment plans. One popular idea is to transplant dopaminergic
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neurons directly into the striatum of a patient with PD. Different options include using healthy tissue
from fetal sources, embryonic stem cells (ESCs), or induced pluripotent stem cells (Hedlund 2009).
Science is also discovering the possibility of deriving dopaminergic neurons from other somatic cells
such as fibroblasts (Cummins and Barker 2012). Much research and experimentation has been done to
determine whether such an idea as transplantation of healthy nervous tissue into the damaged area of the
brain is valid and whether it can ever be a used as a widespread treatment for PD.
Methods:
This study was conducted through obtaining original experimental data on the subject matter.
Acquiring this information was possible through the cross referencing of various articles, the matching
of sources, and the reccomendation of articles by people knowledgable in this area of interest.
Additionally, review articles by noteworthy professionals were also obtained and evaluated.
The
various pieces of data from different sources was then organized by category and verified for its
authenticity and reliability. All the works cited in this study proved to be dependable and accurate
sources.
Current Treatment:
Currently, there are many treatments used to relieve symptoms of Parkinson’s disease. The most
common and effective method is the administration of levodopa (L-Dopa), a chemical which can
convert to dopamine once injected into the brain. For patients of PD, L-Dopa is useful as it alleviates
rigidity and slowness of movement often associated with the disease. However, only 1-5% of levodopa
actually enters the dopamine neurons, and the rest is broken down into dopamine elsewhere in the brain
causing a number of adverse side effects. The main side effect, as observed in more than 50% of PD
patients, is a loss of muscle control or dyskinesia (Hedlund and Perlmann 2009). It has also been found
that the effects of levodopa only last for approximately ten years. Specifically in one study, 50% of
patients exhibited signs of decreased motor ability after being on levodopa for five years and 80% of
patients displayed similar symptoms after ten years. Also, levodopa only targets the deficiency of
dopamine neurons whereas to completely relieve PD patients of symptoms the restoration of other
neurotransmitters may also be important (Hickey and Stacey 2009). Other side effects include low blood
pressure, nausea, gastrointestinal bleeding, and disturbances in breathing. Sometimes levodopa may be
combined with other drugs, such as carbidopa, in order to decrease side effects. Carbidopa decreases
some side effects of levodopa by preventing the conversion of L-dopa to dopamine before reaching the
brain (Rao et al.2006). However, the adverse side effects can never be completely avoided and therefore
the use of levodopa is generally avoided if possible.
Often to temporarily defer treatment of levodopa, a dopamine agonist can be used alternatively.
A dopamine agonist is a chemical that imitates the actions of dopamine. Unlike levodopa, a dopamine
agonist does not convert to dopamine itself, but rather behaves like the neurotransmitter and stimulates
the dopaminergic receptors of the brain. Yet, although the risk of developing dyskinesia is less while
using dopamine agonists, this method is altogether less effective and can cause other issues such as
hallucination, addiction, and drowsiness (Hudlund and Perlmann 2009).
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Another treatment for PD is the use of monoamine oxidase-B inhibitors. Monoamine oxidase is
an enzyme responsible for the breakdown of dopamine in the basal ganglia. By inhibiting this enzyme
using drugs such as selegiline and rasagiline, symptoms of PD can be mildly relieved (Rao et al. 2006).
If a patient does not significantly respond to any medication, or if the side effects are too severe,
deep brain stimulation therapy may also be used. In brief, deep brain stimulation is a surgical procedure
which involves implanting a device to transmit high frequency electrical currents and block abnormal
impulses of the brain. Deep brain stimulation is effective in treating symptoms of PD involving motor
dysfunction. However, like any other form of brain surgery, patients who undergo deep brain
stimulation therapy run the risk of internal bleeding and infection (University of Maryland 2009).
Transplantation

Methodology:
This involves transplanting healthy dopamine neurons directly into the striatum to replace the
dysfunctional tissue and restore motor function in PD patients. However, although this suggestion does
look promising, there are several potential complications that must be taken into consideration. First of
all, it is crucial that the cells survive the transplantation process itself (Hedlund and Perlmann 2009).
Some measures taken to increase survival of the cells have been to incubate the cells together with
growth factors and substances that reduce the risk of cell death. One common substance used is glial cell
line derived neurotrophic factor (GDNF). Another idea is to first increase the number of dopamine
cells by growing them in vitro prior to grafting them into the patient. This growth process not only
proves beneficial by increasing the number of dopamine producing cells, but it also allows for increased
cell differentiation of the graft as this way more dopamine precursor cells are enabled to reach maturity.
In fact, in a study which used dopamine neurons derived in vitro, the chances of the graft survival were
increased based on the cultured growth of the cells before transplantation. In this particular study, the
growth factors used were brain-derived neurotrophic factor (BDNF) together with ascorbic acid and
later GDNF was added amongst other substances such as FGF2, Wnt5a, and FGF20. Results of the
experiment revealed a direct correlation between the growth of cells with growth factors in vitro the
graft survival in vivo (Sanchez-Pernaute et al. 2008). In addition, during the actual transplantation
process, care must be taken to inject the dopamine neurons into strategic multiple locations in the
striatum. This is to ensure that all necessary parts of the brain are innervated and that there is maximal
axonal coverage (Hedlund and Perlmann 2009).
There are many studies being done to determine the optimum cellular composition and
proportional makeup of the graft. Typically, grafted tissue contains a mix of cells including dopamine
cells, a majority of glial cells, GABA and serotonin. Many experimental studies have proven that high
concentrations of dopamine producing cells within the graft are most beneficial for the patient’s
recovery. One particular experiment published in The Journal of Neuroscience yielded results which
support this hypothesis. In animals injected with 6-hydroxydopamine (6-OHDA), an organic synthetic
compound used by researchers to target and destroy dopaminergic neurons in the brain, the ones which
received a graft with the highest amount of dopamine neurons had the highest rate of recovery with the
least side effects. This was in contrast to the animals that were transplanted with tissues of higher
concentrations of serotonin. This group exhibited the most side effects, the main one being graft induced
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dyskinesia. It should be noted that the experiment used control groups to be sure that the success rates of
dopamine were independent of the concentrations of serotonin and vice versa (Carlsonn et. al 2007).
Furthermore, contained within dopaminergic neurons are two subtypes of cells, the A9 neurons,
primarily found in the substantia nigra, and the A10 neurons of the ventral tegmental area, (located on
the floor of the midbrain). Experimental data tends to favor the significance and functionality of the A9
neurons as pertains to PD over the A10 neurons. Yet, there are no techniques that specialize in
purposefully differentiating between the A9 and A10 neurons and therefore their proportional
composition within a graft will vary, resulting in an increased variability of experimental results
(Lindvall and Bjorklund 2012).
It should also be noted that formulation of the cell graft as it is injected into the patient is
significant. Different studies have proven that the method of transplantation, (i.e. suspension of cells,
graft of solid tissue, or pieces), can greatly impact the results of the experiment. In one specific study,
90% of the patients who received grafts through suspension of the cells did not exhibit nearly as many
side effects as those who received transplanted tissue through other methods (Mendez et.al 2005).
Sources of Cells

Fetal Tissue:
The dopamine producing cells grafted into the patient used can be derived from several sources
each with their own advantages and setbacks. Most logically, healthy mesencephalic tissue can be
obtained from aborted fetal embryos. Although this tissue is ideal for its authenticity, the experimental
results from using fetal tissue are extremely varied. One experiment was performed using aborted fetal
embryos taken 6-9 weeks after conception. Tissue from 3-5 donors was transplanted in each patient into
each putamen. According to the UPDRS (Unified Parkinson’s Disease Rating Scale) scores, symptoms
of PD were reduced in these trials by 30-40% and the postoperative need of L-dopa was decreased by
16-45% (Lindvall and Bjorkland 2012). In another trial, similar positive results were also produced.
Embryos of seven weeks old were aborted and the tissue was cultured in preparation for the graft. In this
experiment, however, the patients were divided into two groups. In the first group, tissue was
transplanted unilaterally into both the putamen and caudate, (most of the time the tissue is transplanted
into the putamen since that is the area of the brain sustaining the greatest loss of Dopamine neurons in
PD). In the second experimental group, tissue was transplanted bilaterally into just the putamen.
Although in the end both groups exhibited improvement in motor function, the relief of the groups
receiving the grafts bilaterally was slower to come. In the four to six weeks following the surgery, the
symptoms of these patients actually worsened. The reason for this phenomenon is unclear. To test the
results of the study, positron emission topography was used (PET scan). The PET scan indicated an
increased uptake of fluorodopa. Fluorodopa is an organic compound that is often used as a tool to test
dopamine function and activity. Patients with PD have a low fluorodopa uptake and in this particular
study, all the patients displayed an increase in fluorodopa uptake (Freed et al.2011). This experiment is
especially valid as it tested the effects of transplantation on seven humans each with different health
backgrounds, and symptoms of PD were relieved in each individual case.
Yet, a separate experiment displayed an increased variability of results. In this study, four
patients received unilateral transplants into the caudate nucleus of the brain. After six months following
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the surgery, only three of the patients exhibited signs of improvement while the symptoms of one patient
worsened. Also, any improvement was to a small extent as no drastic recovery was recorded in any of
the four patients tested. Interestingly enough, in this experiment there was a lack of tissue rejection after
the transplant. It could be that using tissue from fetal sources provides the advantage that there is a
decreased risk of immune system rejecting the graft. In this case, it is possible that the mild
improvement can be related to the fact that all the patients were in an advanced state of PD or that not
enough tissue was transplanted due to the lack of availability of fetal sources (Spencer et al. 1992). In
general though, this fluctuation of results caused by using fetal cell sources can be attributed to the
de-standardization of cells in fetal samples. Additionally, tissue from fetal sources is not available in
large enough quantities to be used as a standard procedure as tissue from more than one donor is needed
to treat each patient (Lindvall and Bjorklund 2012). Also, aside from the technical difficulties with using
fetal tissue sources, there are also many ethical issues involved with obtaining the fetal embryonic tissue
(Cummins and Barker 2012). Many believe that the life of a fetal embryo should be considered as much
as the life of an unborn fully developed baby.
Embryonic Stem Cells:
An alternative to the use of fetal tissue, the use of embryonic stem cells (ESCs) seems a more
promising prospect. ESCs are a valuable source since they can be culturally harvested in large quantities
in an undifferentiated state, providing unlimited access to many cell types (Kim et. al 2002).
Nevertheless, this process of inducing ESCs into dopaminergic neurons can be complicated. Many
groups of neurons in the human brain are marked by Tyrosine Hydroxylase. Tyrosine Hydroxylase is a
rate-limiting enzyme involved in the production of dopamine which in turn gives rise to other
catecholamines. Many tyrosine hydroxylase neurons can be derived from ESCs and some even produce
dopamine. However, it is unclear whether those dopaminergic neurons are compatible with the ones of
the substantia nigra lost in PD, and as to whether they can serve as an effective replacement
(Sanchez-Pernaute et al. 2008). Yet, one study did prove successful in improving symptoms of PD
through the process of transplanting ESCs into rats subjected to PD symptoms and conditions. In this
experiment, ESCs were obtained through the process of parthenogenesis, the development of an embryo
without fertilization. This was to avoid many ethical problems typically associated with the use of
embryonic stem cells. The ESCs were first culturally harvested using a variety of growth factors
including brain-derived neurotrophic factor and ascorbic acid. Later on the cells were differentiated by
removing certain proteins involved in organogenesis and stem cell division, such as sonic hedgehog
hemelog, and by adding other specific growth factors and proteins, such as glial cell-derived
neurotrophic factor and dibutyryl cAMP. Finally, the cells were suspended and prepared for the actual
transplantation procedure. The rats were immunosuppressed using cyclosporine A and the grafts were
injected into the right striatum at two locations. To assess the effectiveness of the graft, throughout the
transplantation process the rats were subjected to different behavioral tests specialized to check motor
asymmetry and coordination. Before being grafted with the embryonic stem cells, rats exhibited severe
motor deficits, and after the ESC transplant rats displayed an increased motor ability. To contrast, the
experimental control group did not exhibit any significant change in behavior over time
(Sanchez-Pernaute et. al 2008). This experiment provides hope that the use of ESCs can eventually
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become an acceptable treatment for PD. However, this study cannot determine what the effects of such a
type graft would have on a human. Additionally, it is possible that the experimental evidence would
have differed with a more diverse group of rats each lesioned with 6-OHDA at a different time. (There is
experimental evidence that the effectiveness of the treatment is related to the amount of time the patient
had been suffering from the disease).
Besides the benefits though, there are also a number of potential problems posed through the use
of embryonic stem cells. There is a risk of the graft containing residual undifferentiated embryonic stem
cells which can lead to unwanted growths and tumors. Specifically, this problem was obvious in one
experiment where the amount of dopaminergic neurons in vivo seemed to decrease. This could possibly
be due to the proliferation of residual undifferentiated neurons, as graft overgrowth was observed in the
sample. Further information derived from the study proved that this overgrowth of cells did not result
from pluripotent cells within the body, rather from induced pluripotent stem cells cells that had failed
to differentiate in cultures before the transplant itself. It should be noted that this particular experiment
used the same growth factors and induction strategies as the studies that proved successful, (such as
GDNF, SHH, FGF8 etc.) and no major differences in methodology between other experiments and this
one were apparent. The results of this study encourage extra precautionary measures to be taken while
dealing with the transplantation of ES cells. Safer methods of isolating and restricting composition of the
graft to nerve cell progenitors or mature dopaminergic cells are still being developed. Additionally,
scientists should also be concerned that the new implanted differentiated cells maintain their appropriate
phenotype and survive once inside the CNS (Roy et al. 2006). Sometimes, to prevent or detect this
potential danger, a chemical such as BrdU is used to detect cell division. BrdU is also helpful as it
distinguishes the cells derived in vitro from the cells
in the transplant inside the brain
(Sanchez-Pernaute et al. 2008).
Induced Pluripotent Cells:
Another possible source for obtaining dopamine neurons is through the use of pluripotent stem
cells, or stem cells that have the potential to differentiate into any cell type. Induced pluripotent stem
cells (IPs) can be cultured in large quantities and can be accessed easily from patient donor tissue,
characteristics that make IPs cells seem ideal for use. IPs cells are also useful since they avoid any
ethical issues that can potentially arise through the use of embryonic stem cells or primary fetal tissue.
An additional advantage is that since IPs cell lines are obtained from the patient donor all the genetic
information is matched and no immunosuppressants are needed after transplantation (Hargus et al 2010).
However, similar to the ES cells, induced pluripotent cells require special attention to ensure that they
mature into their desired cell form. Because of this, researchers are developing specific markers and
intrinsic and extrinsic factors in order to identify and induce precursor cells into their appropriate cell
type (Aguila et al.2012). Some examples of proteins used in experimental studies to guide these
undifferentiated stem cells include sonic hedgehog hemelog, and fibroblast growth factor 8. Sonic
hedgehog hemelog is more commonly used by the body to regulate human organogenesis and fibroblast
growth factor 8 also typically plays a key role in regulating biological processes and embryonic
development (Aguila et al. 2012).
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One specific experimental study using IPs cell lines yielded satisfactory results. First, IP cell
lines were obtained from a PD patient. Interestingly enough, the IP cells of a PD patient did not
significantly differ from cells of a healthy person. Then, to test the ability of these stem cells to survive
in vivo, differentiated IP cells were grafted into healthy rats, unlesioned by OHDA-6. All IP cell lines
survived and integrated into the striatum with no evidence of tumor formation or graft overgrowth even
after twelve weeks after transplantation. Finally, grafts derived from IP cell lines were transplanted into
the striatum of a lesioned Parkisonian rat. The grafts contained a large number of dopaminergic neurons
distributed evenly throughout. After the procedure, significant outgrowth and branching of the
transplanted dompaminergic neurons was recorded. The grafted dopamine neurons were tested for
markers such as Girk2 and calbindin and came out positive for most of the neurons. Additionally, no
tumor formation or graft overgrowth was observed in the transplanted cells (Hargus et al.2010).
Although this experiment does seem to promise a future for the use of IP cell lines in treating PD, the
information obtained must be verified by repeated experimentation with identical or similar results. It is
possible that if left for more time the grafts may exhibit signs of overgrowth or tumor formation. Also,
because IP cell lines were originally derived from the patients themselves, there is a risk that the
dopaminergic neurons may lose some function or may display symptoms of PD, (such as the appearance
of Lewy bodies within the graft), given a significant number of years after the initial procedure.
One experiment, in fact, came out with the idea that dopaminergic neurons derived from IP cells
of PD patients are inferior to Da neurons derived from IP cells of a healthy person. Dopaminergic
neurons were taken from IP cells of both a healthy person and a person with PD. The two sets of Da
neurons were then cultured under identical conditions and were subjected to careful analytical watch. In
the end, after a lengthy period of time, the dopaminergic neurons from the PD patient exhibited signs of
neurodegeneration, an increase in apoptosis (cell death), and a decrease in neural branching and
integration. This is an important discovery as it indicates that symptoms of PD are encoded in the
genetic makeup of all the cells of the patient and the disease is not a result of environmental factors
(Sanchez-Danes et al. 2012). Therefore, some researchers suggest that the use of IP cells be restricted to
studying the pathology of PD through cellular modeling and to experimentation in laboratories
(Cummins and Barker 2012).
Reprogramming Fibroblasts:
Recently, science has discovered that it could be possible for one somatic cell to transform into a
completely different type of cell with a different function. Specifically, experimentation is being
performed using fibroblasts (Cummins and Barker 2012). Fibroblasts are a type of cell in the body that
produces the structural matrix outside the cells, supporting them and holding the cells in place.
Fibroblasts are in charge of the production of collagen and are found in the largest quantity in most of
the connective tissue of the body. If a method could be developed for transforming fibroblasts into
dopaminergic neurons it could mean a whole new avenue of treatment for PD patients. An additional
advantage is that if this procedure were possible, the cells could avoid a pluripotent state, eliminating the
danger of graft overgrowth and the risk of tumors. Much experimentation has been done in this area and
many have even proven successful. It should be noted that extra care must be granted to ensure that
within the originating fibroblast material only fibroblast cells are present. If within the sample other cells
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such as neural glia or neural crest cells are existent, they could expand once in the culture and serve as
contaminating material for the remainder of the transplantation process (Pﬁsterer et al.2011). In one
specific study, specific antibodies targeting neural progenitors were employed to rid the fibroblasts of
any unwanted material. Then the fibroblasts were induced into neural cells through certain transcription
factors, (Ascl1, Brn2, and Myt1l). Afterwards though, further specification using viruses was required to
further differentiate the induced neuronal cells into dopaminergic neurons. For this to occur, each cell
had to be exposed to six viruses, including A, B, M, Fuw, Lmx1a, and FoxA2. The percentage of
induced neuronal cells converted into Da neurons turned out to be approximately 10%. This is a
satisfactory achievement although with further study a greater turnout rate can be anticipated. Even
more interesting, though, is the fact that within the original induced neuronal material, no expressions of
tyrosine hydroxylase were found, yet dopaminergic neurons were still able to be induced from these
cells (Pfisterer et al. 2011). It is important to note that a separate experiment performed by Vierbuchen
et al., (2012), used the same four initial transcription factors to induce a pluripotent state from the
fibroblasts and this also proved to be a successful procedure as induced neurons were produced. In
both experiments these induced neuronal cells were deemed functional as they were able to conduct
action potentials and form a performing synapse (Vierbuchen et al. 2012, Pfisterer et al.2011). Also,
similar to IP cells, the use of fibroblast material dodges any ethical concerns typically raised in relation
to stem cell discussions. Using induced neuronal cells for transplantation additionally provides the
benefit that it poses no problems of rejection by the surrounding body tissue. One obstacle, however,
with using this method of induced neuronal cells is that the number of derived Da neurons is solely
dependent on the amount of original fibroblast cells in the starting material. So far, a limited number of
Da neurons have been able to be successfully converted from the fibroblast cells. Further
experimentation, though, should eventually determine precisely the ideal amount of fibroblast cell
starting material (Pfisterer et al.2011).
Risks and Side Effects of Transplantation

Graft Induced Dyskinesia:
Although the idea of transplanting healthy nervous tissue into the striatum of PD patients does
sound like a tempting alternative to the current available treatments for Parkinson’s disease, there are
still a number of remaining challenges and risk factors involved with this method that need to be
resolved before the use of transplantation can become widespread (Hedlund and Perlmann 2009). The
main concern associated with grafting of dopaminergic neurons is graft-induced dyskinesias (GID). It is
suspected that a main cause for this condition is the presence of too much serotonin contained within the
graft. The reason for this hypothesis is that in a healthy functional human brain, dopamine levels are
regulated by the Da transporter and the D2 auto receptor feedback control mechanism. Serotonin is a
particularly significant neurotransmitter since it has the power to convert L-dopa to dopamine,
(Levodopa is always continuously administered to the patient during transplantation with the hopes of
the dosage to be eventually being reduced after the patients show signs of improvement after surgery),
store dopamine in vesicles for later use, and then release the neurotransmitter when seems necessary.
However, when the striatum is damaged and there is a lack of regulatory feedback control, dopamine
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can be released from the serotonin terminals in excessive quantities, possibly causing Graft Induced
dyskinesia (GID) (Carlsson et al.2007).
This hypothesis was proven by Carlsonn et al.(2007) in an experimental study using rats. The
animals were first injected unilaterally with 6-OHDA, transforming them into a model of a human PD
patient. After the lesion the rats were treated with levodopa every day to model dyskinesias in a PD
patient. Twelve weeks later, the rats were divided into four groups. The first group was transplanted
with cells from the anterior portion of the ventral midbrain containing high concentrations of
dopaminergic neuroblasts and low concentrations of serotonergic neuroblasts. The second group
received a graft containing a wider portion of Ventral Midbrain tissue and a larger number of
serotonergic neurons. The third group was grafted with tissue from the dorsal pontine raphe region of
the lower pons. This type of tissue contains high concentrations of serotonergic neurons and very few, if
any at all dopaminergic neurons. Finally, the fourth group was set aside as a control group. In addition,
the experiment included another control group of rats who were lesioned with 6-OHDA but who
received neither the grafts, nor administrations of levodopa. After twenty eight weeks, the rats were
euthanized and their brains were examined. One test detected the presence of TH positivity, a marker for
the outgrowth of dopamine neurons, in each of the samples. The results of this test are displayed in the
picture below. The brains which received the grafts from the ventral midbrain exhibited significant
neuronal outgrowth and integration. Interestingly enough, the graft with a narrower portion from the VM
displayed a greater density of neuronal outgrowth than the sample that contained a wider portion of the
ventral mesencephalon. As predicted, the graft containing tissue from the dorsal pontine raphe region
displayed significant serotonergic neuronal outgrowth but very little TH positivity was detected. The
control groups displayed neither dopaminergic outgrowth nor a presence of serotonin (Carlsonn et al.
2007). After eight weeks, the rats were subjected to behavioral testing to determine whether the
transplant led to any functional and observable improvement. Significant progress was noticed in the
rats who received transplants rich in dopaminergic neurons from the VM whereas little improvement
was observed in the rats who were grafted with tissue from the lower pons. In addition, while on a
continued dosage of L-dopa, the rats who received grafts from the VM exhibited signs of reduced
dyskinesias, whereas the rats who were transplanted with serotonergic tissue displayed worse symptoms
of dyskinesias than prior to the surgery (Carlsson et al.2007).
The results of this experiment clearly indicate the risks of the graft containing serotoninergic
neurons in large amounts. However, it is possible that if the serotonergic neurons were combined in the
graft with high concentrations of dopaminergic neurons then the adverse effects would not prove to be
as severe. This study may have been more productive had they included another experimental group of
rats receiving grafts that were both dopaminergic and serotonergic rich. However, the results of this
study can be relied upon since the results are consistent with numerous other experiments done to
evaluate similar concerns (Carta et al.2010). If methods of transplantation should ever become a
widespread treatment for PD, care must be taken to ensure that the graft contain only the type of cells
that will benefit the patient and not cause graft induced dyskinesia (Hedlund and Perlmann 2009).
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Suggested methods for differentiating between desired and undesired cell types include flourescence
activated cell sorting and Pitx-3 enhanced green flourescent protein (Hedlund et al).
Graft Overgrowth, Tetratoma Formation:
Stem cells (ESCs or IPs) differentiated in vitro with the purpose of being transplanted into a PD
patient at a later time can present many risk factors. The primary concern regarding these cells are the
possibility for residual undifferentiated cells to be grafted into the brain of the patient and then
undergo rapid proliferation (Hedlund and Perlmann 2009). A plausible solution to this potential problem
is to use imaging and filtering techniques to efficiently differentiate and removed the unwanted cells
from the mature desired cells prior to transplantation (Hedlund and Perlmann 2009). One particular
study used biotechniques such Pitx-3 enhanced green flourescent protein and fluorescence-activated
cell sorting to distinguish between cells and isolate mature dopaminergic neurons from less desirable
cell types. In this experiment, it was observed that this method of cell differentiatin is possible and
proved benefical in rat models of PD. Grafts composed of this enhanced cell culture survived longer in
vivo than transplants containing a larger variety of cells with different pluripotencies. In addition, rats
who received these grafts that underwent screening before transplantation experienced greater
symptomatic relief (Hedlund et al.2009). If this filtering method could be employed as successfully as it
was in the experiment by Hedlund et al., then immature cells can be separated from preferred cell types
thus decreasing the risk of tumor formation and graft overgrowth. Of course, however, further repeated
testing is required before such a treatment plan can become accepted. Another possible way to avoid this
problem of tetratoma formation is to use chemicals before transplantation that inhibit the cells’ ability to
replicate (Hedlund and Perlmann 2009). Specifically in one study, the use of mitomycin C, (a chemical
commonly used in chemotherapy), before culturing the cells in vitro eliminated the chances of these
cells proliferating unnecassarily in vivo (Sanchez-Pernaute et al.2008). Even if a chemical is not used
to isolate the desired cells, certain poisons can also rid the culture of any harmful cells before being
transplanted into the PD patient (Hedlund and Perlmann 2009).
Degeneration of Transplanted Tissue:
A major problem often encountered with transplanting healthy dopaminergic tissue into the
striatum of a PD patient is the tendency for the graft to revert back to the previous PD state. This is often
manifested in the observation of Lewy bodies, (a diagnostic characteristic of PD), within the graft. In
most cases the presence of these bodies did not begin to appear until ten years after the transplantation
took place (Hedlund and Perlmann 2009). According to Li et al. (2008), this difficulty poses the
possibility that the disease can be transferred from the cells of the patient into the newly grafted tissue.
One study compared the brain of a PD patient who died fourteen years after receiving a graft, with the
brains of two PD patients who died four years after undergoing the transplantation process. In the brain
of the fourteen year old graft there existed diagnostic features of Parkinson’s Disease such as Lewy
bodies and abnormal protein clusters. In the brains taken four years after the transplant, diagnostic
features of PD did exist yet not at the same level of progression as the fourteen year old grafted brain.
The results of this experiment suggest that the mechanism for the progression of PD is an ongoing
process and can continue to affect even newly grafted tissue in a patient (Kordower et al.2008).
However, it should be noted that in this particular study, only primary fetal tissue was used in the
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patients’ grafts and it is possible that the experiment would have yielded different results if stem cell
tissue would have been used. Additionally, it is unknown whether the results of this study are universal.
Different results could have been possible if a larger experimental sample was used (Kordower et
al.2008). Interestingly enough, in a separate experiment preformed by Mendez et al. (2005), three
subjects were grafted with healthy dopaminergic tissue using very specific methods and techniques,
(graft composition etc.), and the grafts survived without any pathological features for fourteen years.
Another option is that the inclusion of Lewy bodies, and other pathological features of PD such
as neuroinflammation, in grafted tissue can be a result of cellular stress from the surgical grafting
procedure itself (Hedlund and Perlmann 2009). It has been tested and revealed that solid grafts
containing blood vessels are more likely to cause cellular stress and induce immunoreactivity in the
brain than grafts that do not contain blood vessels (Hedlund and Perlmann 2009). It is noteworthy that
the experiment by Mendez et al.2005,in which the grafts did not exhibit signs of degeneration, the
transplanted tissue did not contain any blood vessels. However, this idea can only explain the presence
of Lewy bodies in relatively young brains and does not give reason for the degeneration of tissue in
older samples.
Discussion:
Parkinson’s disease is a condition characterized by a loss of dopaminergic neurons in the pars
compacta of the substancia nigra in the human midbrain. Symptoms of PD include rigidity, and a loss of
motor ability and coordination. Currently, there are many treatments available for patients of
Parkinson’s disease. However, due to the many side effects and imperfections associated with the
existing treatments, science is now researching alternative options. Primarily, many studies have been
done on the subject of transplanting healthy dopaminergic tissue directly into the striatum of a PD
patient. Various options include the use of primary fetal tissue, embryonic stem cells, or induced
pluripotent cells. Additionally, science has recently proposed the idea of reprogramming fibroblasts
directly into nervous tissue. However, the results of each of these methods are highly varied and the
methodology must be perfected before the use of this treatment can become widespread. Also, there are
many risks and potential problems that must be resolved before the use of transplantation can be
available as a standard treatment for PD. Such side effects include graft induced diskinesia, graft
overgrowth, and the degeneration of the grafted tissue. Although there is still much to be improved and
perfected in this area of treatment for PD, hopefully, with the appropriate dedication to the field and
further testing and experimentation, patients with Parkinson’s disease can fully recover from their
symptoms and experience risk-free relief.
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